天天基金网·2025-08-06 06:33Group 1 - The core viewpoint of the article highlights the significant movements in the U.S. stock market, particularly the decline of major indices and the rise of pharmaceutical stocks due to proposed tariffs on imported drugs by President Trump [1][5][4] Group 2 - On August 5, the U.S. stock market saw all three major indices decline, with the Dow Jones Industrial Average falling by 0.14% to 44,111.74 points, the S&P 500 down 0.49% to 6,299.19 points, and the Nasdaq Composite dropping 0.65% to 20,916.55 points [2] - The ISM reported that the U.S. services PMI for July was 50.1, below market expectations of 51.5 and the previous month's 50.8, indicating near stagnation in service sector growth [2] - Employment indicators within the services sector fell from 47.2 to 46.4, marking the lowest level since the COVID-19 pandemic began [2] - The prices for materials and services surged to 69.9, the highest since October 2022 [2] Group 3 - Pharmaceutical stocks experienced notable gains, with Pfizer rising over 5% and UnitedHealth Group increasing by over 4% following Trump's announcement regarding tariffs on imported drugs [5][4] - Trump indicated that the initial tariffs would be small, but could rise to 150% within a year and potentially reach 250% thereafter, aiming to encourage domestic drug production [5][4] Group 4 - The European Union announced a suspension of planned retaliatory tariffs against the U.S., originally set to take effect on August 7, while still retaining the option to reinstate them [7] - EU officials expressed dissatisfaction with the recent trade agreement with the U.S., suggesting that the EU should adopt a firmer stance [8]